Pulse Biosciences, Inc. PLSE
Pulse Biosciences, Inc. (Nasdaq: PLSE) is a cardio-renal-metabolic drug developer. Its lead program, nPulse Cardiac Catheter System, is in Phase 3 for Paroxysmal atrial fibrillation. Its next catalyst on record is nPulse Cardiac Catheter System: Pivotal study data readout and PMA submission (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: nPulse Cardiac Catheter System — Pivotal study data readout and PMA submission (date not stated). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Vybrance Percutaneous Electrode System | Benign thyroid nodules (soft tissue ablation) | device-combination | Approved |
| nPulse Cardiac Catheter System | Paroxysmal AF | device-combination | Phase 3 |
| nPulse Cardiac Surgical Clamp | Atrial fibrillation (concomitant surgical procedures) | device-combination | Phase 3 |
Recent results and decisions
- Nov 6, 2026met Interim six-month results from PRECISE-BTN study show 86% of patients achieved at least 50% nodule volume reduction after nsPFA treatment.
86% of patients achieved the primary endpoint of at least 50% nodule volume reduction at six months.
Filing - Sep 30, 2026completed enrollment Pulse Biosciences completed enrollment in NANOPULSE-AF, the U.S. IDE pivotal study of the nPulse Cardiac Catheter System for atrial fibrillation, with 169 evaluable patients at 15 sites.
Completed enrollment in NANOPULSE-AF, the U.S. IDE pivotal study of the nPulse Cardiac Catheter System for the treatment of atrial fibrillation (AF), with 169 evaluable patients at 15 sites with 36 investigators.
Filing - Sep 30, 2026completed enrollment Pulse Biosciences completed enrollment of the PRECISE-Benign Thyroid Nodule study in September with 100 patients.
Completed enrollment of the PRECISE-Benign Thyroid Nodule (PRECISE-BTN) study in September with 100 patients.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.